Maravai LifeSciences Holdings, Inc. (MRVI) Cash Flow Statement

The persistent gap between net income and operating cash flow indicates that reported losses are heavily influenced by non-cash items, likely including depreciation and amortization from the company's significant capital investments. Investors should monitor whether this divergence narrows as the company moves past its post-pandemic restructuring phase, as current figures make it difficult to assess true operational profitability.

The inconsistency in FCF margins suggests that the company's cost structure is not yet fully aligned with its current revenue base. This volatility warrants further investigation into whether the recent return to positive FCF in 2026Q1 represents a sustainable trend or merely a temporary benefit from timing differences in working capital.

The high level of capital intensity relative to revenue suggests that the company is burdened by fixed costs associated with its San Diego facilities. Unless revenue growth accelerates to improve asset utilization, these maintenance-heavy capital requirements may continue to pressure the company's ability to achieve consistent free cash flow.

The erratic nature of these working capital swings may indicate challenges in managing inventory levels for specialized reagents in a post-COVID demand environment. Investors should monitor whether the company can optimize its cash conversion cycle to prevent further liquidity strain during periods of revenue contraction.